Medico-House Ray Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 3 Year, 3 Months
- Last Filing with ROC 31 Mar 2022
About Medico-House Ray Pharmaceutical
Medico-House Ray Pharmaceutical Private Limited (MRPPL) is a Private Limited Indian Non-Government Company incorporated in India on 13 October 2021 (Three years and three months 19 days old ). Its registered office is in Bhojpur, Bihar, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rakesh Ray and Bikku Ray serve as directors at the Company.
Company Details
- Location
Bhojpur, Bihar, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U85100BR2021PTC054630
- Company No.
054630
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Oct 2021
- Date of AGM
20 Dec 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Who are the key members and board of directors at Medico-House Ray Pharmaceutical?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rakesh Ray  | Director | 13-Oct-2021 | Current |
| Bikku Ray | Director | 13-Oct-2021 | Current |
Financial Performance of Medico-House Ray Pharmaceutical.
Enhance accessibility to Medico-House Ray Pharmaceutical's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Medico-House Ray Pharmaceutical?
Unlock access to Medico-House Ray Pharmaceutical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Ray Technobuild Construction Private LimitedRakesh Ray is a mutual person
- Ray Infravision Private Limited
Rakesh Ray is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Medico-House Ray Pharmaceutical?
Medico-House Ray Pharmaceutical has a workforce of 0 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medico-House Ray Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medico-House Ray Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.